Fatty liver drug trial halted early: what we know

NCT ID NCT04004325

Terminated Disease control Sponsor: Forma Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an experimental drug called FT-4101 in 14 overweight or obese adults with NASH, a serious fatty liver disease. The main goals were to check safety and see if the drug could reduce liver fat. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONALCOHOLIC STEATOHEPATITIS (NASH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NONALCOHOLIC STEATOHEPATITIS (NASH) OVERWEIGHT OR OBESITY

Contacts and locations

Locations

Catalina Research Institute

Montclair, California, 91763, United States
ProSciento, Inc.

Chula Vista, California, 91911, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.